Preoperative Oral Carbohydrate Loading and Gastrointestinal Recovery After Bariatric Surgery in Metabolic Syndrome
Preoperative Oral Carbohydrate Loading for Enhanced Gastrointestinal Recovery After Bariatric Surgery in Patients With Metabolic Syndrome
This prospective randomized controlled trial aims to evaluate the effect of preoperative oral carbohydrate loading on postoperative gastrointestinal recovery in patients with metabolic syndrome undergoing bariatric surgery. Eligible participants will be randomly assigned to either a preoperative oral carbohydrate drink group or a standard preoperative fasting group.
The primary objective of this study is to determine whether preoperative oral carbohydrate loading can facilitate early postoperative gastrointestinal recovery. Outcome measures will include the proportion of patients achieving postoperative gastrointestinal recovery, time to postoperative gastrointestinal recovery, perioperative blood glucose levels, and other postoperative recovery-related outcomes. This study aims to provide clinical evidence regarding the efficacy and safety of preoperative oral carbohydrate loading in patients with metabolic syndrome undergoing bariatric surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This prospective, randomized trial aims to evaluate the efficacy and safety of preoperative oral carbohydrate loading for postoperative gastrointestinal recovery in patients with metabolic syndrome undergoing bariatric surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either the preoperative oral carbohydrate loading group or the placebo group.
Participants in both groups will follow a standardized preoperative fasting protocol, with solid food prohibited for at least 6 hours before induction of anesthesia and clear liquids discontinued 2 hours before surgery. Participants in the POC group will consume 400 mL of an oral carbohydrate-containing beverage 2 hours before surgery, whereas participants in the control group will consume an equal volume of a placebo beverage with a similar appearance and taste but containing no carbohydrates at the same time point.
The primary outcome is postoperative gastrointestinal functional recovery, assessed using the GI-3 criteria. GI-3 recovery is defined as tolerance of oral intake accompanied by recovery of lower gastrointestinal function. The study will evaluate both the proportion of participants achieving GI-3 recovery within the predefined postoperative period and the time to GI-3 recovery.
Secondary outcomes include other measures related to postoperative gastrointestinal recovery, postoperative nausea and vomiting, quality of recovery, length of hospital stay, and other postoperative recovery-related outcomes. Perioperative blood glucose levels and glycemic variability will be assessed to evaluate the metabolic safety of preoperative oral carbohydrate loading.
Safety outcomes related to preoperative oral carbohydrate intake will also be assessed. Gastric ultrasonography will be performed before induction of anesthesia to evaluate gastric volume, corrected gastric volume, gastric antral cross-sectional area, and Perlas grade. The occurrence of perioperative regurgitation or pulmonary aspiration will also be recorded.
This study aims to determine whether, compared with placebo, preoperative oral carbohydrate loading can enhance postoperative gastrointestinal recovery in patients with metabolic syndrome undergoing bariatric surgery without increasing clinically significant perioperative glycemic fluctuations or aspiration-related risks.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Wei Ke, PhD
- Número de teléfono: +86 13883904332
- Correo electrónico: wk202448@hospital-cqmu.com
Ubicaciones de estudio
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Porcelana, 400016
- The First Affiliated Hospital of Chongqing Medical University（No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China）
-
Contacto:
- Ren Li, PhD
- Número de teléfono: 8618323187421
- Correo electrónico: renli177@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- adults aged 18-65 years;
- diagnosis of metabolic syndrome (≥3 of the following: elevated waist circumference, elevated triglycerides, elevated blood pressure, elevated fasting glucose, and reduced HDL-C);
- eligibility for bariatric surgery(body mass index ≥35 kg/m² or metabolic disease with body mass index 27.5-34.9 kg/m²), with planned Roux-en-Y gastric bypass or sleeve gastrectomy;
- provision of written informed consent and willingness to complete follow-up.
Exclusion Criteria:
- gastrointestinal motility disorders;
- severe cardiovascular, pulmonary, hepatic, or renal dysfunction;
- HbA1c ≥8.0%;
- fasting plasma glucose >10.0 mmol/L at the preoperative assessment;
- malnutrition;
- known allergy to carbohydrate preparations;
- pregnancy or lactation;
- previous bariatric or gastrointestinal surgery;
- chronic use of medications known to substantially affect gastrointestinal motility.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: POC Group
Fasted from solid foods for ≥6 hours (≥8 hours after fatty or meat-containing meals), with clear liquids permitted until 2 hours before surgery, and consumed 400 mL of a carbohydrate-containing clear liquid 2 hours before surgery.
|
Participants in the POC group were fasted from solid foods for ≥6 hours (≥8 hours after fatty or meat-containing meals), with clear liquids permitted until 2 hours before surgery, and consumed 400 mL of a carbohydrate-containing clear liquid 2 hours before surgery.
The beverage provided 12.5 g of carbohydrates per 100 mL and contained no fiber, protein, or fat.
|
|
Comparador de placebos: Control Group
Fasted from solid foods for ≥6 hours (≥8 hours after fatty or meat-containing meals), with clear liquids permitted until 2 hours before surgery, and consumed 400 mL of a non-caloric, carbohydrate-free clear liquid with a similar appearance and taste 2 hours before surgery.
|
Participants in the placebo group were instructed to follow the same preoperative fasting regimen and to consume 400 mL of a matching non-caloric, carbohydrate-free clear liquid 2 hours before surgery.
The placebo was similar to the carbohydrate-containing beverage in appearance and taste，but contained no carbohydrates, fiber, protein, or fat.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
GI-3 recovery rate within 72 hours after surgery
Periodo de tiempo: Within 72 hours after surgery
|
GI-3 is a composite endpoint defined as the ability to tolerate oral intake (consumption of food and drink at three consecutive meals without significant nausea or vomiting), accompanied by flatus or defecation.
|
Within 72 hours after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to GI-3 recovery
Periodo de tiempo: From the end of surgery up to 7 days after surgery.
|
From the end of surgery up to 7 days after surgery.
|
|
|
Time to GI-2 recovery
Periodo de tiempo: From the end of surgery up to 7 days after surgery.
|
GI-2 is a composite endpoint defined as the ability to tolerate oral intake (consumption of food and drink at three consecutive meals without significant nausea or vomiting), accompanied by defecation
|
From the end of surgery up to 7 days after surgery.
|
|
Postoperative Nausea and Vomiting Score
Periodo de tiempo: Days 1 - 4 postoperatively
|
Postoperative nausea and vomiting were assessed using the Postoperative Nausea and Vomiting Score, ranging from 0 to 6, with higher scores indicating more severe postoperative nausea and vomiting.
|
Days 1 - 4 postoperatively
|
|
15-item Quality of Recovery Score
Periodo de tiempo: Days 1 - 7 and 30 postoperatively
|
Quality of recovery was assessed using the 15-item Quality of Recovery Score, ranging from 0 to 150, with higher scores indicating better postoperative recovery.
|
Days 1 - 7 and 30 postoperatively
|
|
Perioperative blood glucose levels
Periodo de tiempo: Measured before anesthesia induction, 1 hour after incision, before leaving the operating room, and 1 hour after surgery.
|
Measured before anesthesia induction, 1 hour after incision, before leaving the operating room, and 1 hour after surgery.
|
|
|
Glycemic variability
Periodo de tiempo: Calculated based on blood glucose levels measured before anesthesia induction, 1 hour after incision, before leaving the operating room, and 1 hour after surgery.
|
Calculated based on blood glucose levels measured before anesthesia induction, 1 hour after incision, before leaving the operating room, and 1 hour after surgery.
|
|
|
Time to first postoperative flatus
Periodo de tiempo: From the end of surgery up to 7 days after surgery.
|
From the end of surgery up to 7 days after surgery.
|
|
|
Time to first postoperative defecation
Periodo de tiempo: From the end of surgery up to 7 days after surgery.
|
From the end of surgery up to 7 days after surgery.
|
|
|
Total length of hospital stay (including readmissions within 30 days after surgery)
Periodo de tiempo: Within 30 days after surgery
|
Within 30 days after surgery
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Unplanned readmission rate within 30 days after surgery
Periodo de tiempo: Within 30 days after surgery
|
Within 30 days after surgery
|
|
|
Postoperative complications
Periodo de tiempo: Within 30 days after surgery
|
Classified according to the Clavien-Dindo classification criteria for complications
|
Within 30 days after surgery
|
|
Gastric cross-sectional area (CSA)
Periodo de tiempo: Before anaesthetic induction
|
Calculated using the formula (AP × CC × π)/4, where AP is the anteroposterior diameter and CC is the craniocaudal diameter.
|
Before anaesthetic induction
|
|
Gastric volume
Periodo de tiempo: Before anaesthetic induction
|
= 27.0 + 14.6 × CSA - 1.28 × age
|
Before anaesthetic induction
|
|
Perlas grade
Periodo de tiempo: Before anaesthetic induction
|
Graded according to the Perlas system: grade 0 (no content in either position), grade 1 (only a small amount of fluid visible in the right lateral decubitus position), and grade 2 (distended antrum with fluid visible in both positions).
|
Before anaesthetic induction
|
|
Corrected gastric volume (CGV)
Periodo de tiempo: Before anaesthetic induction
|
Recalculated in mL kg-¹
|
Before anaesthetic induction
|
|
Incidence of regurgitation or aspiration
Periodo de tiempo: From anesthesia induction to discharge from the post-anesthesia care unit.
|
From anesthesia induction to discharge from the post-anesthesia care unit.
|
Colaboradores e Investigadores
Investigadores
- Director de estudio: Wei Ke, PhD, First Affiliated Hospital of Chongqing Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- POC-MetS-2026-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .